CD19 and acute lymphoblastic leukemia: Recently, trispecific CD19/20/22-CAR-T cells that target B-ALL cells irrespectively of CD19 loss both in vitro and in an NSG xenograft model have been proposed as a salvage therapy or even front-line therapy in B-ALL [108].